Myriad Genetics (MYGN) Given a $44.00 Price Target at BTIG Research

BTIG Research set a $44.00 price target on Myriad Genetics (NASDAQ:MYGN) in a report released on Wednesday. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently commented on the stock. Leerink Swann upped their target price on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a market perform rating in a research note on Wednesday. Morgan Stanley upped their target price on shares of Myriad Genetics from $26.00 to $28.00 and gave the stock an underweight rating in a research note on Wednesday. Goldman Sachs Group began coverage on shares of Myriad Genetics in a research note on Monday, January 29th. They issued a sell rating and a $32.00 target price on the stock. Barclays upped their target price on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an equal weight rating in a research note on Monday, January 22nd. Finally, BidaskClub upgraded shares of Myriad Genetics from a buy rating to a strong-buy rating in a research note on Saturday, January 20th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Myriad Genetics currently has an average rating of Hold and a consensus target price of $31.42.

Shares of Myriad Genetics (MYGN) opened at $32.96 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.05 and a quick ratio of 2.06. Myriad Genetics has a 1 year low of $15.71 and a 1 year high of $41.57. The firm has a market cap of $2,278.52, a PE ratio of 17.82, a P/E/G ratio of 2.41 and a beta of 0.32.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.07. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The company had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. During the same period in the prior year, the company posted $0.26 EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. equities research analysts predict that Myriad Genetics will post 1.15 earnings per share for the current fiscal year.

In other news, Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Richard M. Marsh sold 13,759 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the transaction, the vice president now owns 136,385 shares in the company, valued at $4,943,956.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,064 shares of company stock worth $2,679,097. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership bought a new position in shares of Myriad Genetics during the fourth quarter valued at approximately $1,975,000. UBS Asset Management Americas Inc. boosted its stake in shares of Myriad Genetics by 5.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 50,954 shares of the company’s stock valued at $1,750,000 after purchasing an additional 2,615 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Myriad Genetics by 1.5% during the fourth quarter. BlackRock Inc. now owns 10,066,753 shares of the company’s stock valued at $345,743,000 after purchasing an additional 150,003 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Myriad Genetics by 18.1% during the fourth quarter. Rhumbline Advisers now owns 162,219 shares of the company’s stock valued at $5,571,000 after purchasing an additional 24,839 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Myriad Genetics by 227.7% during the fourth quarter. Arizona State Retirement System now owns 116,380 shares of the company’s stock valued at $3,997,000 after purchasing an additional 80,870 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics (MYGN) Given a $44.00 Price Target at BTIG Research” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/10/myriad-genetics-mygn-given-a-44-00-price-target-at-btig-research.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply